Skip to main content
. 2015 Mar 26;6(13):10978–10993. doi: 10.18632/oncotarget.3452

Table 4. Altered transcript expression in PTC samples as compared to benign counterparts from the same donors (multinodular goiter cases).

Gene P-value (PTC vs benign) P-value with FDR (PTC vs benign) Fold change Total number of samples Number of samples with expression value > 50 (linear scale)
Without consideration of clinical aggressiveness
CHEK1 2.63 × 10−4 1.15 × 10−3 2.05 48 47
c-KIT 2.38 × 10−6 2.39 × 10−5 −3.23 48 48
c-MET 2.66 × 10−6 2.39 × 10−5 2.73 48 48
TIMP1 2.00 × 10−3 6.00 × 10−3 2.01 48 48
With consideration of clinical aggressiveness: more aggressive PTC (group II in Table 2)
BCL2 3.08 × 10−6 1.38 × 10−5 −2.11 26 26
BMAL1 7.30 × 10−4 1.64 × 10−3 1.93 26 26
CHEK1 1.32 × 10−3 2.08 × 10−3 2.16 26 26
c-KIT 1.59 × 10−6 9.63 × 10−6 −4.25 26 26
c-MET 5.64 × 10−11 1.02 × 10−9 4.55 26 26
PPARγ 1.59 × 10−3 2.21 × 10−3 −2.81 26 25
TG 1.60 × 10−6 9.63 × 10−6 −3.03 26 26
TIMP1 1.22 × 10−5 4.38 × 10−5 3.38 26 26